Share This Page
Drug Price Trends for PREGABALIN ER
✉ Email this page to a colleague
Average Pharmacy Cost for PREGABALIN ER
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| PREGABALIN ER 82.5 MG TABLET | 72888-0049-30 | 4.20287 | EACH | 2024-12-18 |
| PREGABALIN ER 165 MG TABLET | 72205-0078-30 | 2.50858 | EACH | 2024-12-18 |
| PREGABALIN ER 330 MG TABLET | 72205-0079-30 | 3.19707 | EACH | 2024-12-18 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
PREGABALIN ER Market Analysis and Financial Projection
Pregabalin ER Market Analysis and Price Projections
Market Overview
The pregabalin market, including its extended-release (ER) formulations, is poised for significant growth driven by several key factors. Here are the critical aspects of the market analysis and price projections for pregabalin ER.
Market Size and Growth Projections
The global pregabalin market, which includes both immediate and extended-release formulations, was valued at approximately USD 1.6 billion in 2022 and is projected to reach USD 2.2 billion by 2032, growing at a CAGR of 3% from 2023 to 2032[4].
For the specific period of 2024-2031, the market is expected to grow from USD 824.75 million to USD 1,088.56 million, with a CAGR of 3.53%[5].
Regional Market Analysis
North America
North America dominates the pregabalin market in terms of revenue, driven by advanced healthcare infrastructure, substantial investments in R&D, and the presence of major industry players. The high prevalence of epilepsy and related disorders in the United States, where 2.3 million adults and over 450,000 children and teenagers suffer from epilepsy, further fuels market growth in this region[1].
Asia Pacific
The Asia Pacific region is expected to register the fastest CAGR during the forecast period. This growth is attributed to the rising incidence of epilepsy, neuropathic pain, and other related conditions in countries like China, India, and Southeast Asian nations. The region's rapid technological advancements, increasing healthcare expenditures, and government support for scientific research also contribute to the market's expansion[4].
Dosage Forms and Applications
Extended Release Formulations
Extended-release formulations of pregabalin, such as oral tablets, are gaining traction due to their ease of administration and patient preference. These formulations are particularly beneficial for managing chronic conditions like epilepsy, neuropathic pain, and anxiety disorders[5].
Applications
Pregabalin ER is primarily used for the management and treatment of epilepsy, neuropathic pain, anxiety disorders, and fibromyalgia. The rising prevalence of these conditions globally, especially in low- and middle-income countries where access to treatment is often limited, drives the demand for pregabalin ER[4].
Price Projections
Current Pricing
The prices of pregabalin ER formulations vary based on dosage and quantity. For example, a 30-day supply of 82.5 mg pregabalin oral tablets, extended release, can range from $280.40 to $536.39, depending on the supplier and availability[2].
Future Pricing Trends
While specific price projections for pregabalin ER are not provided, the overall market trend suggests that prices may stabilize or slightly decrease due to the increasing availability of generic pregabalin products. The surge in generic approvals is expected to enhance competition, potentially leading to more affordable options for consumers[4].
Key Players and Market Strategies
Major players in the pregabalin market include Teva Pharmaceuticals, Cipla Limited, Medley Pharmaceuticals Limited, Viatris Inc., and Amneal Pharmaceuticals LLC. These companies are focusing on product launches, especially of various tablets and extended-release formulations, to cater to the growing demand. Collaborations between local and global players, particularly in the Asia Pacific region, are also driving market growth through increased generic availability and innovative formulation developments[1][4].
Regulatory and Healthcare Accessibility
Government initiatives aimed at enhancing healthcare accessibility and affordability are crucial for market growth. In regions like Asia Pacific, governmental support for scientific research and collaborations between local and global players are propelling the adoption of pregabalin technologies, including ER formulations[4].
Patient Epidemiology and Unmet Needs
According to the World Health Organization, epilepsy affects over 50 million individuals worldwide, with up to 70% of people living with epilepsy potentially avoiding seizures with proper diagnosis and care. However, in low-income countries, a significant portion of people with epilepsy do not receive the necessary therapy, highlighting a substantial unmet need that the pregabalin market aims to address[4].
Conclusion
The pregabalin ER market is poised for growth, driven by increasing prevalence of related disorders, advancements in healthcare infrastructure, and the rising availability of generic products. As the market expands, particularly in regions like Asia Pacific, the demand for effective and affordable treatments like pregabalin ER is expected to rise.
Key Takeaways
- Market Size: The global pregabalin market is projected to reach USD 2.2 billion by 2032.
- CAGR: Expected CAGR ranges from 3% to 3.53% during the forecast period.
- Regional Growth: Asia Pacific is the fastest-growing region, while North America holds the largest market share.
- Dosage Forms: Extended-release formulations are gaining traction due to ease of administration.
- Applications: Primarily used for epilepsy, neuropathic pain, anxiety disorders, and fibromyalgia.
- Price Trends: Prices may stabilize or decrease due to increasing generic availability.
Frequently Asked Questions
What is the current market size of the pregabalin market?
The global pregabalin market was valued at approximately USD 1.6 billion in 2022[4].
Which region is expected to grow the fastest in the pregabalin market?
The Asia Pacific region is expected to register the fastest CAGR during the forecast period[4].
What are the primary applications of pregabalin ER?
Pregabalin ER is primarily used for the management and treatment of epilepsy, neuropathic pain, anxiety disorders, and fibromyalgia[5].
Who are the major players in the pregabalin market?
Major players include Teva Pharmaceuticals, Cipla Limited, Medley Pharmaceuticals Limited, Viatris Inc., and Amneal Pharmaceuticals LLC[1].
How is the availability of generic pregabalin products affecting the market?
The surge in generic approvals is expected to enhance competition, potentially leading to more affordable options for consumers and driving market growth[4].
Sources:
- Mordor Intelligence - Pregabalin Market Size & Share Analysis - Growth Trends
- Drugs.com - Pregabalin Prices, Coupons, Copay Cards & Patient Assistance
- Introspective Market Research - Pregabalin Market-Current Analysis by Market Share
- Allied Market Research - Pregabalin Market Size, Segments Analysis | Forecast - 2032
- Data Bridge Market Research - Global Pregabalin Market – Industry Trends and Forecast to 2031
More… ↓
